Author : adminDate : 2019-12-03 16:14

Promethera announces Clinical Phase 2a of HepaStem at AASLD (11/11/2019)

- Promethera, a Belgian stem-cell medicine development company, announces the result of HepaStem’s Europe clinical phase 2a (aimed at patients with Acute-on-chronic liver failure (ACLF)) at American Associationfor the Study of Liver Diseases (AASLD) holding in Boston from November 8th to 12th.

- The following clinic was individually progressed by Promethera in Europe and evaluated the safety and efficacy of HepaStem.

- HepaStem is a liver-derived stem cell developed by Promethera and Lifeliver Inc. (an affiliated company of HLB Life Science) owns a domestic copyright.

Link: https://www.promethera.com/press-releases/view/promethera-biosciences-attend-upcoming-scientific-and-partnering